BR112015028516A2 - tratamento ou prevenção de distúrbios neurodegenerativos com o uso de mentol, linalol e/ou icilina - Google Patents
tratamento ou prevenção de distúrbios neurodegenerativos com o uso de mentol, linalol e/ou icilinaInfo
- Publication number
- BR112015028516A2 BR112015028516A2 BR112015028516A BR112015028516A BR112015028516A2 BR 112015028516 A2 BR112015028516 A2 BR 112015028516A2 BR 112015028516 A BR112015028516 A BR 112015028516A BR 112015028516 A BR112015028516 A BR 112015028516A BR 112015028516 A2 BR112015028516 A2 BR 112015028516A2
- Authority
- BR
- Brazil
- Prior art keywords
- neurodegenerative disorders
- iciline
- menthol
- prevention
- treatment
- Prior art date
Links
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 title abstract 5
- 208000015122 neurodegenerative disease Diseases 0.000 title abstract 4
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 title abstract 3
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 title abstract 3
- 229940041616 menthol Drugs 0.000 title abstract 3
- 230000002265 prevention Effects 0.000 title abstract 3
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 title abstract 2
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 title abstract 2
- 229930007744 linalool Natural products 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
- C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C33/00—Unsaturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
- C07C33/02—Acyclic alcohols with carbon-to-carbon double bonds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C35/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring
- C07C35/02—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring monocyclic
- C07C35/08—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring monocyclic containing a six-membered rings
- C07C35/12—Menthol
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361827243P | 2013-05-24 | 2013-05-24 | |
| PCT/EP2014/060632 WO2014187942A1 (en) | 2013-05-24 | 2014-05-23 | Treatment or prevention of neurodegenerative disorders using menthol, linalool and/or icilin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112015028516A2 true BR112015028516A2 (pt) | 2017-07-25 |
Family
ID=50819727
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015028516A BR112015028516A2 (pt) | 2013-05-24 | 2014-05-23 | tratamento ou prevenção de distúrbios neurodegenerativos com o uso de mentol, linalol e/ou icilina |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20160108004A1 (enExample) |
| EP (1) | EP3003291A1 (enExample) |
| JP (1) | JP2016524608A (enExample) |
| CN (1) | CN105228602A (enExample) |
| AU (1) | AU2014270338A1 (enExample) |
| BR (1) | BR112015028516A2 (enExample) |
| CA (1) | CA2908402A1 (enExample) |
| WO (1) | WO2014187942A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6719574B2 (ja) | 2016-02-22 | 2020-07-08 | ニュートリシャス ベー．フェー．Ｎｅｗｔｒｉｃｉｏｕｓ Ｂ．Ｖ． | 神経変性疾患の、予防または治療のための組成物 |
| IL265902B2 (en) | 2016-10-11 | 2024-04-01 | Gbs Global Biopharma Inc | Cannabinoid-containing complex mixtures for the treatment of neurodegenerative diseases |
| CN109674851A (zh) * | 2017-10-18 | 2019-04-26 | 大江生医股份有限公司 | 薄荷精油的应用 |
| CN107789349A (zh) * | 2017-12-01 | 2018-03-13 | 新乡医学院 | 治疗阿尔海默氏综合症的药物组合物及其应用 |
| JP7641973B2 (ja) * | 2020-03-24 | 2025-03-07 | 中国▲医▼薬大学 | 神経変性疾患及び脳卒中を改善する外用組成物の調製に用いられるメントールの用途 |
| JP7194484B2 (ja) * | 2020-10-21 | 2022-12-22 | 三井農林株式会社 | 脳機能改善剤 |
| CN116919930A (zh) * | 2022-04-06 | 2023-10-24 | 沈阳药科大学 | 萜类化合物在调节脑膜淋巴循环促进脑内异常蛋白通过淋巴途径清除中的应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6177472B1 (en) * | 1995-08-08 | 2001-01-23 | University Of Alabama At Birmingham Research Foundation | Regulation of alzheimer's disease proteins and uses thereof |
| JP4742204B2 (ja) * | 2005-01-21 | 2011-08-10 | 財団法人ヒューマンサイエンス振興財団 | 脂肪細胞分化制御剤 |
| JP2007302572A (ja) * | 2006-05-09 | 2007-11-22 | Pokka Corp | 脳機能改善剤及びそれを含有する脳機能改善組成物 |
| JP2008231049A (ja) * | 2007-03-22 | 2008-10-02 | Saburo Yasuda | アポトーシス誘導物質 |
| KR20090085237A (ko) * | 2008-02-04 | 2009-08-07 | 김병문 | 천연 진주가루를 함유한 뇌질환 예방 및 치료용 한약조성물 |
| WO2009137818A1 (en) * | 2008-05-09 | 2009-11-12 | Mount Sinai School Of Medicine Of New York University | Methods for preventing and treating neurodegenerative diseases |
| KR101189763B1 (ko) * | 2010-06-10 | 2012-10-10 | 고려대학교 산학협력단 | 리나룰을 포함하는 중추신경계 장애의 예방, 치료, 또는 개선용 조성물 |
| KR20120103317A (ko) * | 2011-03-10 | 2012-09-19 | 한국생명공학연구원 | 아실 코에이:콜레스테롤 아실트랜스퍼라제 저해활성을 갖는 고수씨 추출물 또는 이로부터 분리된 리나로올을 포함하는 조성물 |
| EP2846815A4 (en) * | 2012-05-07 | 2016-01-20 | Israel State | GERANIUM OIL AND INGREDIENTS THEREOF FOR THE TREATMENT OF NEURODEEGENERATIVE ILLNESSES |
-
2014
- 2014-05-23 WO PCT/EP2014/060632 patent/WO2014187942A1/en not_active Ceased
- 2014-05-23 JP JP2016514429A patent/JP2016524608A/ja active Pending
- 2014-05-23 AU AU2014270338A patent/AU2014270338A1/en not_active Abandoned
- 2014-05-23 CN CN201480029668.7A patent/CN105228602A/zh active Pending
- 2014-05-23 BR BR112015028516A patent/BR112015028516A2/pt not_active IP Right Cessation
- 2014-05-23 EP EP14726346.1A patent/EP3003291A1/en not_active Withdrawn
- 2014-05-23 CA CA2908402A patent/CA2908402A1/en not_active Abandoned
- 2014-05-23 US US14/892,004 patent/US20160108004A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20160108004A1 (en) | 2016-04-21 |
| JP2016524608A (ja) | 2016-08-18 |
| CA2908402A1 (en) | 2014-11-27 |
| EP3003291A1 (en) | 2016-04-13 |
| WO2014187942A1 (en) | 2014-11-27 |
| CN105228602A (zh) | 2016-01-06 |
| AU2014270338A1 (en) | 2015-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX389242B (es) | Compuestos para su uso en el tratamiento de trastornos neuromusculares | |
| BR112015022462A8 (pt) | inibidores de ido, composição farmacêutica, método de inibição de atividade de indolamina 2,3-dioxigenase e uso dos referidos inibidores | |
| BR112015011456A2 (pt) | compostos de aminopirimidina como inibidores de egfr mutantes contendo t790m | |
| BR112015028879A8 (pt) | compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos | |
| BR112015022417A2 (pt) | métodos e composições para inibição de proteínas contendo bromodomínio | |
| BR112016003201A2 (pt) | inibidores de grp94 seletivos e usos dos mesmos | |
| EA201692506A3 (ru) | Ингибиторы репликации вирусов гриппа | |
| BR112015028516A2 (pt) | tratamento ou prevenção de distúrbios neurodegenerativos com o uso de mentol, linalol e/ou icilina | |
| BR112015021999A2 (pt) | inibidores de indoleamina 2,3-dioxigenase (ido) | |
| HK1213264A1 (zh) | 经取代的苯化合物 | |
| BR112015022197A8 (pt) | uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia | |
| EA201600204A1 (ru) | Производные хиназолина, фармацевтическая композиция на их основе и их применение для профилактики или лечения опухоли | |
| EA201592024A1 (ru) | Замещенные 5-(3,5-диметилизоксазол-4-ил)-индолин-2-оны | |
| BR112016011065A8 (pt) | composto cristalino, composição farmacêutica, forma de dosagem, método para tratar anemia | |
| BR112015029090A2 (pt) | compostos de 3,4-di-hidroisoquinolin-2(1h)-ila | |
| BR112018005905A2 (pt) | ?composto, composição farmacêutica, métodos para evitar ou tratar uma doença ou condição, lesões de órgão, hepatotoxicidade e fígado gorduroso, e, uso de um composto? | |
| BR112015026297A2 (pt) | terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer | |
| BR112014019704A8 (pt) | Compostos inibidores de hsp90 c-terminais, composição farmacêutica compreendendo os ditos compostos e uso dos mesmos para o tratamento ou prevenção de um distúrbio neurodegenerativo | |
| EA201690039A1 (ru) | Ингибиторы rorc2 и способы их применения | |
| BR112017026535A2 (pt) | composto de fórmula estrutural i, enantiômero isolado, composição farmacêutica, método para inibir atividade do transportador de monocarboxilato mct4, método para inibir seletivamente atividade do transportador de monocarboxilato mct4, método para tratar um distúrbio mediado por transportador de monocarboxilato mct4 e uso de um composto | |
| BR112016027043A8 (pt) | combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer | |
| EA201591180A1 (ru) | Составы ингибитора lfa-1 | |
| BR112016007462A2 (pt) | fitonutrientes anti-inflamatórios para uso no tratamento ou prevenção de sinovite | |
| BR112015001096A2 (pt) | derivados de di e tri-heteroaril como inibidores de agregação de proteína | |
| EA201791432A1 (ru) | Композиции на основе пролекарства монометилфумарата |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2516 DE 26-03-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |